Identification of distinctive interferon gene signatures in different types of myositis
Citation Manager Formats
Make Comment
See Comments
This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Abstract
Objective Activation of the type 1 interferon (IFN1) pathway is a prominent feature of dermatomyositis (DM) muscle and may play a role in the pathogenesis of this disease. However, the relevance of the IFN1 pathway in patients with other types of myositis such as the antisynthetase syndrome (AS), immune-mediated necrotizing myopathy (IMNM), and inclusion body myositis (IBM) is largely unknown. Moreover, the activation of the type 2 interferon (IFN2) pathway has not been comprehensively explored in myositis. In this cross-sectional study, our objective was to determine whether IFN1 and IFN2 pathways are differentially activated in different types of myositis by performing RNA sequencing on muscle biopsy samples from 119 patients with DM, IMNM, AS, or IBM and on 20 normal muscle biopsies.
Methods The expression of IFN1- and IFN2-inducible genes was compared between the different groups.
Results The expression of IFN1-inducible genes was high in DM, moderate in AS, and low in IMNM and IBM. In contrast, the expression of IFN2-inducible genes was high in DM, IBM, and AS but low in IMNM. The expression of IFN-inducible genes correlated with the expression of genes associated with inflammation and muscle regeneration. Of note, ISG15 expression levels alone performed as well as composite scores relying on multiple genes to monitor activation of the IFN1 pathway in myositis muscle biopsies.
Conclusions IFN1 and IFN2 pathways are differentially activated in different forms of myositis. This observation may have therapeutic implications because immunosuppressive medications may preferentially target each of these pathways.
Glossary
- AS=
- antisynthetase syndrome;
- CK=
- creatine kinase;
- DM=
- dermatomyositis;
- FPKM=
- fragments per kilobase of transcript per million mapped reads;
- HMGCR=
- 3-hydroxy-3-methylglutaryl-CoA reductase;
- IBM=
- inclusion body myositis;
- IFN=
- interferon;
- IMNM=
- immune-mediated necrotizing myopathy;
- JAK=
- Janus kinase;
- MDA=
- melanoma differentiation-associated protein;
- MSA=
- myositis-specific autoantibodies;
- NXP=
- nuclear matrix protein;
- SRP=
- signal recognition particle;
- STAT=
- signal transducer and activator of transcription;
- TIF=
- transcriptional intermediary factor
Footnotes
Go to Neurology.org/N for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article.
- Received January 29, 2019.
- Accepted in final form April 30, 2019.
- © 2019 American Academy of Neurology
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
For assistance, please contact:
AAN Members (800) 879-1960 or (612) 928-6000 (International)
Non-AAN Member subscribers (800) 638-3030 or (301) 223-2300 option 3, select 1 (international)
Sign Up
Information on how to subscribe to Neurology and Neurology: Clinical Practice can be found here
Purchase
Individual access to articles is available through the Add to Cart option on the article page. Access for 1 day (from the computer you are currently using) is US$ 39.00. Pay-per-view content is for the use of the payee only, and content may not be further distributed by print or electronic means. The payee may view, download, and/or print the article for his/her personal, scholarly, research, and educational use. Distributing copies (electronic or otherwise) of the article is not allowed.
Letters: Rapid online correspondence
- Reader response: Identification of distinctive interferon gene signatures in different types of myositis
- Kenichiro Taira, Neurologist, National Center Hospital, National Center of Neurology and Psychiatry
Submitted December 05, 2019
REQUIREMENTS
If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Use of Whole-Genome Sequencing for Mitochondrial Disease Diagnosis
Dr. Robert Pitceathly and Dr. William Macken
► Watch
Related Articles
- No related articles found.
Topics Discussed
Alert Me
Recommended articles
-
Article
More prominent muscle involvement in patients with dermatomyositis with anti-Mi2 autoantibodiesIago Pinal-Fernandez, Christopher A. Mecoli, Maria Casal-Dominguez et al.Neurology, October 08, 2019 -
Article
Muscular and extramuscular features of myositis patients with anti-U1-RNP autoantibodiesMaria Casal-Dominguez, Iago Pinal-Fernandez, Andrea M. Corse et al.Neurology, March 01, 2019 -
Article
Pathologic Features of Anti-Mi-2 DermatomyositisJantima Tanboon, Michio Inoue, Shinya Hirakawa et al.Neurology, December 04, 2020 -
Article
Muscular and extramuscular clinical features of patients with anti-PM/Scl autoantibodiesRebecca De Lorenzo, Iago Pinal-Fernandez, Wilson Huang et al.Neurology, May 04, 2018